Lopresor^® SR.

The active ingredient is Di-[(±)-1-(isopropylamino)-3-[p-2(methoxyethyl)phenoxy]-2-propanol] L(+)-tartrate (metoprolol tartrate). One coated slow release tablet contains 200mg metoprolol tartrate.

Film coated tablets.

For the treatment of hypertension, angina pectoris, prophylaxis of migraine.

Lopresor SR Tablets should be administered orally and swallowed unchewed.

The dose must always be adjusted to the individual requirements of the patient but should not exceed 400mg/day.

The following are the guidelines:

Adults

Hypertension: One Lopresor SR Tablet should be given in the morning. Most patients may be expected to respond satisfactorily within 14 days. Further antihypertensive effect may be achieved by the addition of a diuretic or a vasodilator.

Lopresor SR may be administered with benefit to both previously untreated patients with hypertension and to those in whom the response to previous therapy is inadequate. In the latter type of patient therapy may be continued and Lopresor SR added into the regime with adjustment of previous therapy if necessary.

Angina pectoris: Initially, one Lopresor SR Tablet daily. The dose may be increased to two tablets once daily if required. In general a significant improvement in exercise tolerance and a reduction of anginal attacks may be expected with a dose of one Lopresor SR Tablet daily.

Prophylaxis of migraine: One tablet daily given in the morning.

Elderly: There is no evidence to suggest that dosage requirements are different in otherwise healthy elderly patients. However, caution is indicated in elderly patients as an excessive decrease in blood pressure or pulse rate may cause the blood supply to vital organs to fall to inadequate levels.

In patients with significant hepatic dysfunction the lower dosage recommendations will be more appropriate.

Children: Not recommended.

Known hypersensitivity to metoprolol and related derivatives or to any of the excipients, severe asthma or history of severe bronchospasm, atrioventricular block of second or third degree, uncontrolled heart failure, clinically relevant sinus bradycardia, sick-sinus syndrome, severe peripheral arterial disease, cardiogenic shock, hypotension, untreated phaeochromocytoma, metabolic acidosis.

Metoprolol is also contraindicated when myocardial infarction is complicated by significant bradycardia, first degree heart block, systolic hypotension (less than 100mmHg) and/or severe heart failure.

A warning stating “Do not take this medicine if you have a history of wheezing or asthma” will appear on the label.

Although cardioselective beta-blockers, including Lopresor, may have less effect on lung function than non selective beta-blockers, as with all beta-blockers these should be avoided in patients with reversible obstructive airway disease unless there are compelling clinical reasons for their use. Therapy with a beta₂-stimulant may become necessary or current therapy require adjustment.

Metoprolol may aggravate bradycardia and symptoms of peripheral arterial circulatory disorders. If the patient develops increasing bradycardia (heart rate less than 50 to 55 beats/min), Lopresor SR should be given in lower doses or gradually withdrawn.

In addition, anaphylactic reactions precipitated by other agents may be particularly severe in patients taking β-blockers, and may be resistant to normal doses of adrenaline. Whenever possible, β-blockers, including Lopresor, should be avoided for patients who are at increased risk of anaphylaxis.

Abrupt cessation of therapy with a beta-blocker should be avoided, especially in patients with ischaemic heart disease. When possible, Lopresor SR should be withdrawn gradually over a period of 10 days, the doses diminishing to 25mg for the last 6 days. During its withdrawal the patient should be kept under close surveillance and replacement therapy should be initiated when required.

Beta-blockers, including Lopresor, should not be used in patients with untreated congestive heart failure (see “Contraindications”). This condition should first be stabilised. Additional therapy e.g. diuretics and/or digitalisation should also be considered for patients with a history of heart failure or patients who are known to have a poor cardiac reserve.

Because of their negative effect on atrioventricular conduction, β-blockers, including Lopresor, should be given only with caution to patients with first degree atrioventricular block (see “Contraindications”).

Beta-blockers mask some of the clinical signs of thyrotoxicosis. Therefore, Lopresor SR should be administered with caution to patients having, or suspected of developing, thyrotoxicosis, and both thyroid and cardiac function should be monitored closely

Lopresor SR should be used with caution in patients with diabetes mellitus, especially those who are receiving insulin or oral hypoglycaemic agents (see “Interactions with other medicaments and other forms of interaction”). In labile and insulin-dependent diabetes it may be necessary to adjust the hypoglycaemic therapy. Lopresor SR may mask some of the symptoms of hypoglycaemia by inhibition of sympathetic nerve functions and patients should be warned accordingly.

In patients with a treated phaeochromocytoma, an alpha-blocker should be given concomitantly.

In patients with significant hepatic dysfunction it may be necessary to adjust the dosage because metoprolol undergoes biotransformation in the liver.

The administration of adrenaline to patients undergoing beta-blockade can result in an increase in blood pressure and bradycardia although this is less likely to occur with beta₁-selective drugs.

Lopresor SR therapy should be brought to the attention of the anaesthetist prior to general anaesthesia. The benefits of continuing a treatment with a beta-blocker, including Lopresor, should be balanced against the risk of withdrawing it in each patient. When it has been decided to interrupt a beta-blockade in preparation for surgery, therapy should be discontinued for at least 24 hours. Continuation of beta-blockade reduces the risk of arrhythmias during induction and intubation. However, the risk of hypertension may be increased. If treatment is continued, caution should be observed with the use of certain anaesthetic drugs. In a patient under beta-blockade, the anaesthetic selected should be one exhibiting as little negative inotropic activity as possible (halothane/nitrous oxide). The patient may be protected against vagal reactions by intravenous administration of atropine.

Beta-blockers may increase the number and duration of angina attacks in patients with Prinzmetal's angina (variant angina pectoris). However, relatively selective β₁-receptor blockers, such as Lopresor SR, can be used in such patients, but only with the utmost care.

The full oculomucocutaneous syndrome, as described elsewhere with practolol, has not been reported with Lopresor SR. However, part of this syndrome (dry eyes either alone or, occasionally, with skin rashes) has occurred. In most cases the symptoms cleared when Lopresor SR treatment was withdrawn. Patients should be observed carefully for potential ocular effects. If such effects occur, discontinuation of Lopresor SR should be considered (see advice about discontinuation above).

The effects of metoprolol and other antihypertensive drugs on blood pressure are usually additive, and care should be taken to avoid hypotension. However, combinations of antihypertensive drugs may often be used with benefit to improve control of hypertension.

As beta-blockers may affect the peripheral circulation, care should be exercised when drugs with similar activity, e.g. ergotamine are given concurrently.

Care should also be exercised when beta-blockers are given in combination with sympathetic ganglion blocking agents, other beta blockers (also in the form of eye drops) or MAO inhibitors.

Prazosin

The acute postural hypotension that can follow the first dose of prazosin may be increased in patients already taking a beta-blocker.

Clonidine

If combination treatment with clonidine is to be discontinued metoprolol should be withdrawn several days before clonidine.This is because the hypertension that can follow withdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment.

Calcium channel blockers

Calcium channel blockers such as verapamil and diltiazem may potentiate the depressant effects of β-blockers on blood pressure, heart rate, cardiac contractility and atrioventricular conduction. A calcium channel blocker of the verapamil (phenylalkylamine) type should not be given intravenously to patients receiving Lopresor SR because there is a risk of cardiac arrest in this situation. Patients taking an oral calcium channel blocker of the verapamil type in combination with Lopresor SR should be closely monitored.

CYP2D6 inhibitors

Potent inhibitors of this enzyme may increase the plasma concentration of metoprolol. (see section 5.2. Pharmacokinetic properties). Caution should therefore be exercised when co-administering potent CYP2D6 inhibitors with metoprolol. Known clinically significant potent inhibitors of CYP2D6 are antidepressants such as fluoxetine, paroxetine or bupropion, antipsychotics such as thioridazine, antiarrhythmics such as propafenone, antiretrovirals such as ritonavir, antihistamines such as diphenhydramine, antimalarials such as hydroxychloroquine or quinidine, antifungals such as terbinafine and medications for stomach ulcers such as cimetidine.

Class I anti-arrhythmic drugs and amiodarone

Amiodarone, propafenone, and other class I anti-arrhythmic agents such as quinidine and disopyramide may potentiate the effects of beta-blockers on heart rate and atrioventricular conduction.

Nitroglycerin

Nitroglycerin may enhance the hypotensive effect of Lopresor SR.

Digitalis glycosides

Concurrent use of digitalis glycosides may result in excessive bradycardia and/or increase in atrioventricular conduction time

Sympathomimetics

Metoprolol will antagonise the beta₁ effects of sympathomimetic agents but should have little influence on the bronchodilator effects of beta₂-agonists at normal therapeutic doses.

Insulin and oral hypoglycaemic drugs

In diabetic patients who use insulin, beta-blocker treatment may be associated with increased or prolonged hypoglycaemia. Beta-blockers may also antagonise the hypoglycaemic effects of sulfonylureas. The risk of either effect is less with a beta₁-selective drug such as Lopresor SR than with a non-selective beta-blocker. However, diabetic patients receiving Lopresor SR should be monitored to ensure that diabetes control is maintained (see also “Special warnings and special precautions for use”)

Non-steroidal anti-inflammatory drugs

Concurrent treatment with non-steroidal anti-inflammatory drugs such as indomethacin may decrease the antihypertensive effect of metoprolol

Lignocaine

Metoprolol may impair the elimination of lignocaine.

General anaesthetics

Some inhalation anaesthetics may enhance the cardiodepressant effect of beta-blockers (see “Special warnings and special precautions for use”).

Hepatic enzyme inducers/inhibitors

Enzyme inducing agents (e.g. rifampicin) may reduce plasma concentrations of metoprolol, whereas enzyme inhibitors (e.g. cimetidine) may increase plasma concentrations.

Alcohol

During concomitant ingestion of alcohol and metoprolol the concentration of blood alcohol may reach higher levels and may decrease more slowly.

Beta-blockers reduce placental perfusion which may result in intrauterine foetal death, immature and premature deliveries. Lopresor SR should not be used in pregnancy or lactation unless it is considered that the benefit outweighs the possible risk to the foetus/infant.

Metoprolol has, however, been used in pregnancy associated hypertension under close supervision after 20 weeks gestation. Although the drug crosses the placental barrier and is present in cord blood no evidence of foetal abnormalities have been reported. Animal experiments have shown neither teratogenic potential nor other adverse events on the embryo and/or foetus relevant to the safety assessment of the product.

The amount of metoprolol ingested via breast milk seems to be negligible with regard to its beta-blocking effects if the mother is treated in doses within the therapeutic range.

If Lopresor SR is used during pregnancy and lactation special attention should be paid to the foetus, neonate and breast-fed infant for undesirable effects of the drug's beta-blocking action (e.g. bradycardia, hypoglycaemia). The lowest possible dose should be used, and treatment should be discontinued at least 2 to 3 days before delivery to avoid increased uterine contractility and effects of β-blockade in the newborn baby.

As with all beta-blockers, metoprolol may affect patients ability to drive and operate machinery. Patients should be warned accordingly.

Frequency estimates: very common 10%; common 1% and < 10%; uncommon 0.1% and < 1%; rare 0.01% and < 0.1%; very rare < 0.01%.

Post Marketing Experience

The following adverse reactions have been reported during post-approval use of Lopresor: confusional state, an increase in blood triglycerides and a decrease in high density lipoprotein (HDL). Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.

Signs and symptoms

In more severe cases an overdosage of metoprolol may lead to severe hypotension, sinus bradycardia, atrioventricular block, heart failure, cardiogenic shock, cardiac arrest, bronchospasm, impairment of consciousness, coma, convulsions, nausea, vomiting, cyanosis, hypoglycaemia and occasionally hyperkalaemia.

The first manifestations of overdosage appear 20 minutes to 2 hours after ingestion of Lopresor SR. The effects of massive overdose may persist for several days, despite declining plasma concentrations.

Treatment

Patients should be admitted to hospital and, generally, should be managed in an intensive care setting, with continuous monitoring of cardiac function, blood gases, and blood biochemistry. Emergency supportive measures such as artificial ventilation or cardiac pacing should be instituted if appropriate. Even apparently well patients who have taken a small overdose should be closely observed for signs of poisoning for at least 4 hours.

In the event of a potentially life-threatening oral overdose, use induction of vomiting or gastric lavage (if within 4 hours after ingestion of Lopresor SR) and/or activated charcoal to remove the drug from the gastrointestinal tract. Metoprolol can not be effectively removed by haemodialysis.

Atropine may be given intravenously to control significant bradycardia. Intravenous β-agonists such as prenalterol or isoprenaline should be used to treat bradycardia and hypotension; very high doses may be needed to overcome the β-blockade. Dopamine, dobutamine or noradrenaline may be given to maintain blood pressure. Glucagon has positive inotropic and chronotropic effects on the heart that are independent of β-adrenergic receptors, and has proved effective in the treatment of resistant hypotension and heart failure associated with β-blocker overdose.

Diazepam is the drug of choice for controlling seizures. A β₂-agonist or aminophylline can be used to reverse bronchospasm; patients should be monitored for evidence of cardiac arrhythmias during and after administration of the bronchodilator.

Pharmacotherapeutic group

Lopresor SR is a cardioselective beta-adrenagergic receptor blocking agent.

Mechanism of action

It has a relatively greater blocking effect on beta₁-receptors (i.e. those mediating adrenergic stimulation of heart rate and contractility and release of free fatty acids from fat stores) than on beta₂-receptors, which are chiefly involved in broncho- and vasodilation.

It has no membrane-stabilising effect nor partial agonist (intrinsic sympathomimetic) activity.

The stimulant effect of catecholamines on the heart is reduced or inhibited by metoprolol. This leads to a decrease in heart rate, cardiac contractility and cardiac output.

Absorption

Lopresor SR is well absorbed after oral administration, peak plasma concentrations occurring 4-5 hours after dosing. The bioavailability of a single dose is approximately 50%, increasing to approximately 70% during repeated administration. The bioavailability also increases if metoprolol is given with food.

Distribution and Biotransformation

Approximately 10% of metoprolol in plasma is protein bound. Metoprolol crosses the placenta, and is found in breast milk (see “Pregnancy and lactation”).

Metoprolol is extensively metabolised by enzymes of the cytochrome P450 system in the liver. The oxidative metabolism of metoprolol is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6). There are marked ethnic differences in the prevalence of the poor metabolisers (PM) phenotype. Approximately 7% of Caucasians and less than 1% Orientals are PMs.

CYP2D6 poor metabolisers exhibit several-fold higher plasma concentrations of metoprolol than extensive metabolisers with normal CYP2D6 activity. None of the metabolites of metoprolol contribute significantly to its beta-blocking effect.

Elimination

Elimination is mainly by hepatic metabolism and the average elimination half-life is 3.5 hours (range 1 to 9 hours). Rates of metabolism vary between individuals, with poor metabolisers (approximately 10%) showing higher plasma concentrations and slower elimination than extensive metabolisers. Within individuals, however, plasma concentrations are stable and reproducible.

Characteristics in patients

Because of variation in rates of metabolism, the dose of metoprolol should always be adjusted to the individual requirements of the patient. At the therapeutic response, adverse effects and relative cardioselectivity are related to plasma concentration, poor metabolisers may require lower than normal doses. Dosage adjustment is not routinely required in the elderly or in patients with renal failure, but dosage may need to be reduced in patients with significant hepatic dysfunction when metoprolol elimination may be impaired.

There are no further data of relevance to the prescriber which are additional to that already included in other sections of the Summary of Product Characteristics.

The coated tablets contain silicon dioxide, microcrystalline cellulose, calcium phosphate, polyacrylic/methacrylic copolymer, magnesium stearate, stearic acid, hydroxypropyl methylcellulose, glyceryl palmitostearate, talc, titanium dioxide, polysorbate and yellow iron oxide.

None known.

Five years.

No special recommendations.

Medicines should be kept out of reach of children.

The tablets are pale yellow, capsule shaped, biconvex, film coated tablets, one face imprinted CG/CG, the other face with the letters CDC/CDC and packed in PVC/PVdC/foil bubble packs of 28 tablets, or PVC/PE/PVDC/ALU blister packs of 28 tablets.

None.

Recordati Pharmaceuticals Limited

Isis House

43 Station Road

Henley-on-Thames

Oxfordshire

RG9 1AT

UK

PL 25046/0011

08 December 1980 / 22 October 2003

06/10/2010